Norges Bank Day One Biopharmaceuticals, Inc. Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$12.03 - $17.69 $2.03 Million - $2.99 Million	169,000 New	169,000 $2.33 Million
Q4 2023 Feb 09, 2024	BUY	$9.68 - $15.37 $1.64 Million - $2.6 Million	169,000 New	169,000 $2.47 Million
Q3 2023 Nov 13, 2024	BUY	$11.22 - $14.86 $1.9 Million - $2.51 Million	169,000 New	169,000 $2.07 Million
Q1 2023 May 15, 2024	BUY	$12.75 - $23.41 $2.15 Million - $3.96 Million	169,000 New	169,000 $2.26 Million
Q4 2022 Feb 14, 2023	BUY	$18.77 - $22.0 $2.03 Million - $2.38 Million	108,000 New	108,000 $2.32 Million

178

84M

144K

218K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $1B
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.